Pronova, Apotex Strike Deal Over Generic Lovaza

Law360, New York (March 30, 2011, 5:28 PM ET) -- Apotex Corp. on Tuesday agreed to hold off on manufacturing a generic version of Lovaza until 2015 to resolve Norwegian pharmaceutical company Pronova BioPharma Norge AS' patent infringement claims over the triglyceride-lowering drug.

In separate stipulations of dismissal without prejudice, the parties agreed to voluntarily drop Pronova's two infringement suits that were scheduled to begin the first phase of trial in the U.S. District Court for the District of Delaware on Tuesday, with each party bearing its own attorneys' fees and costs.

Although the stipulation did...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required